23vPS

also known as PPSV23

today NCT00962780 · Ph 3 NCT00980655 · Ph 3

201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT00962780	Mar 2010 → Apr 2013	HIV infectious disease, pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT00980655	Jan 2010 → May 2013	—	Pfizer	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT00546572 Comparator	Nov 2007 → Jul 2010	pneumococcal infection	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded

Every value below carries the sentence it was read from. 4 sources stand behind the page.

Field	Value	Cited text
Known as	23vPS	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00980655 ↗ 2 NCT00546572 ↗ NCT00962780 ↗
Known as	PPSV23	“one dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) at 1-month intervals” PMID 25888646 ↗ Jul 2015
Modality	Vaccine	“23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine” NCT00546572 ↗
Route	Intramuscular	“0.5-mL dose 23vPS will be administered into the deltoid muscle at year 0” NCT00546572 ↗